两年逐渐减量托珠单抗疗程对巨细胞动脉炎患者的有效性:单中心前瞻性研究
该单中心前瞻性研究纳入23例巨细胞动脉炎患者,托珠单抗每周给药12个月、每两周给药12个月后停用,评估减量与停药可行性;停药后6个月内6例(26%)复发,结论认为两年逐渐减量方案可有效诱导并维持缓解,但停药后相当比例患者复发。
要点
- 23例巨细胞动脉炎患者接受托珠单抗每周12个月、每两周12个月后停药。
- 停药后6个月内6例(26%)复发;用药期间复发轻微且对治疗调整有应答。
- 未发现新的或非预期安全性事件。
核心结论
- 两年逐渐减量托珠单抗方案可有效诱导并维持巨细胞动脉炎缓解。
- 托珠单抗治疗期间复发轻微,对治疗增量调整有应答。
- 停药后6个月内有相当比例患者复发。
研究设计与样本
- 单中心前瞻性研究,纳入符合托珠单抗治疗条件的巨细胞动脉炎患者23例。
- 托珠单抗前12个月每周给药,随后12个月每两周给药,之后停用。
- 主要结局为托珠单抗停用后第6个月无复发生存。
主要发现
- 托珠单抗启动原因为复发(n=14)、持续活动(n=5)或激素相关不良事件(n=4)。
- 前12个月内4例(17%)临床复发;每两周给药期间2例(9%)复发。
- 停药后6个月内6例(26%)复发。
- 停药时无患者接受激素治疗,18FDG-PET/CT无活动性血管炎征象。
- 未发现新的或非预期安全性事件。
关键数值与推荐
- 托珠单抗启动时2例正在使用甲氨蝶呤并维持;每两周给药开始时4例使用甲氨蝶呤。
- 14例在18FDG-PET/CT上有颅外血管受累。
- 每两周给药开始时全部患者临床缓解,2例18FDG-PET/CT有活动性血管炎,2例接受激素治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the feasibility of tocilizumab tapering and withdrawal in patients with giant cell arteritis (GCA). METHODS: GCA patients eligible for tocilizumab were prospectively enrolled. Tocilizumab was administered weekly for the first 12 months, every-other-week for an additional 12 months, then discontinued. Relapses on tocilizumab were managed with temporary increases in systemic glucocorticoids or addition of methotrexate. Primary outcome was relapse-free survival at month 6 after tocilizumab suspension. Relapse-free survival on tocilizumab, imaging response, and adverse events were evaluated. RESULTS: 23 GCA patients were enrolled. Reasons for tocilizumab start were relapse (n = 14), persistence of activity (n = 5), or steroid-related adverse events (n = 4). At tocilizumab start, two patients were on methotrexate, which was maintained. Fourteen patients had extracranial vascular involvement on 18FDG-PET/CT. During the first 12 months, four patients (17%) had clinical relapse. At every-other-week tocilizumab start, all patients were in clinical remission, two patients had active vasculitis on 18FDG-PET/CT; two patients were on steroid therapy, and four patients were taking methotrexate. Two patients (9%) relapsed while on every-other-week tocilizumab. At tocilizumab suspension, no patient was on steroid therapy and no patient had signs of active vasculitis on 18FDG-PET/CT. In the 6 months after tocilizumab discontinuation, six patients (26%) relapsed. No new or unexpected safety findings were identified. CONCLUSION: Tocilizumab tapered over a two-year period was effective to induce and maintain remission in GCA. Relapses on tocilizumab were minor and responded to incremental changes in therapy. A significant proportion of patients relapsed in the 6 months after therapy suspension.
引用
- Tomelleri A, Campochiaro C, Farina N, et al. Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study. Semin Arthritis Rheum. 2023. PMID: 36774660. doi:10.1016/j.semarthrit.2023.152174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。